Added to YB: 2026-04-30
Pitch date: 2026-04-27
TMDX [neutral]
TransMedics Group, Inc.
-8.44%
current return
Author Info
No bio for this author
Company Info
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally.
Market Cap
$3.5B
Pitch Price
$107.66
Price Target
N/A
Dividend
N/A
EV/EBITDA
24.82
P/E
20.78
EV/Sales
5.83
Sector
Health Care Equipment and Supplies
Category
growth
36% of the U.S. Liver Market Already Belongs to TMDX — And the Ceiling Is Still Far Away
TMDX (holding update): Q4 rev $160.8M (+32% YoY), FY25 rev $605.5M (+37% YoY). OCS Liver dominates w/ 36% US mkt share (vs 26% in '24), 4,197 cases. Op margin expanded 940bps to 17.9% via operating leverage. $488M cash, zero debt risk. 2026 guide $727-757M (+20-25%) excludes ENHANCE/DENOVO catalysts, EU expansion. NOP fleet (22 jets, 79% coverage) = replicable moat. Liver registry pubs pending in high-impact journals could drive adoption. Risks: Q3 seasonality, ENHANCE Part B delays, int'l ramp slower. Thesis intact.
Read full article (9 min)